Drug/Small Molecule:
folic acid

2D structure

Overview

Generic Names: Folate; PGA; Pteroyl-L-glutamic acid; Pteroyl-L-monoglutamic acid; Pteroylglutamic acid; Pteroylmonoglutamic acid; Vitamin B9; Vitamin Bc; Vitamin Be; Vitamin M
Trade Names: Acifolic; Apo-Folic; Cytofol; Dosfolat B activ; Folacid; Folacin; Folbal; Folcidin; Foldine; Folettes; Foliamin; Folicet; Folipac; Folsan; Folsaure; Folsav; Folvite; Folvron; Incafolic; Millafol
PharmGKB Accession Id: PA449692

Description

A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (poaceae). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. PubChem (source: Drug Bank)

Indication

For treatment of folic acid deficiency, megaloblastic anemia and in anemias of nutritional supplements, pregnancy, infancy, or childhood. (source: Drug Bank)

ATC Therapeutic Category

  • B03BB:Folic acid and derivatives

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase. These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase. (source: Drug Bank)

Pharmacology

Folic acid, a water-soluble B-complex vitamin, is found in foods such as liver, kidneys, yeast, and leafy, green vegetables. Folic acid is used to diagnose folate deficiency and to treat topical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic (source: Drug Bank)

Protein Binding

Very high to plasma protein (source: Drug Bank)

Toxicity

IPR-MUS LD<sub>50</sub> 85 mg/kg,IVN-GPG LD<sub>50</sub> 120 mg/kg, IVN-MUS LD<sub>50</sub> 239 mg/kg, IVN-RAT LD<sub>50</sub> 500 mg/kg, IVN-RBT LD<sub>50</sub> 410 mg/kg (source: Drug Bank)

Isomeric SMILES Code:

c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(nc(n3)N)O (source: Drug Bank)

In-Depth Annotations (In-Depth Annotation)

  1. rs1801131 at chr1:11777063 in MTHFR
    Well studied, associated with multiple phenotypes.
    Variant Name:
    MTHFR:1298A>C
    Related Drugs:
    folic acid, methotrexate
    Evidence:
    http://www.pharmgkb.org/.../variant.jsp
  2. rs1801133 at chr1:11778965 in CLCN6, MTHFR
    Well studied, associated with multiple phenotypes.
    Variant Name:
    MTHFR:677C>T
    Related Drugs:
    fluorouracil, folic acid, methotrexate
    Evidence:
    http://www.pharmgkb.org/.../variant.jsp#ImportantVariantInformationforMTHFR-677CT

Curated Annotations (Curated Annotation)

  1. rs1801131 at chr1:11777063 in MTHFR
    At 6 months methotrexate and folic acid therapy, of early rheumatoid arthritis patients with the MTHFR 1298AA genotype showed good improvement relative to combined CA and AA genotypes (OR 2.3), while 1298C allele carriers developed more adverse drug events (OR 2.5) (e.g. pneumonitis, gastrointestinal ADEs, skin and mucosal ADEs, and elevated liver enzyme levels). Patients with MTHFR 1298AA / 677CC diplotype showed greater clinical improvement.
    Variant Name:
    MTHFR:1298A>C
    Related Drugs:
    folic acid, methotrexate
    Related Diseases:
    Arthritis, Rheumatoid
    Evidence:
    PMID:16572443
  2. rs1801131 at chr1:11777063 in MTHFR
    In 330 patients who completed 3 months methotrexate treatment for psoriasis, no significant genotypic associations were found between clinical outcome (e.g. efficacy, toxicity) and 50 SNPs in pathway genes for methotrexate metabolism (ATIC, FPGS, GGH, MTHFR), including 47 common ( >5% minor allele frequency) haplotype-tagging SNPs (r(2) > 0.8) plus 3 additional SNPs.
    Variant Name:
    MTHFR:298A>C
    Related Drugs:
    folic acid, methotrexate
    Related Diseases:
    Psoriasis
    Evidence:
    PMID:19016697
  3. rs1801133 at chr1:11778965 in CLCN6, MTHFR
    Given methotrexate and folic acid therapy, patients with the MTHFR 1298AA / 677CC diplotype showed greater clinical improvement for early rheumatoid arthritis.
    Variant Name:
    MTHFR:677C>T
    Related Drugs:
    folic acid, methotrexate
    Related Diseases:
    Arthritis, Rheumatoid
    Evidence:
    PMID:16572443
  4. rs1801133 at chr1:11778965 in CLCN6, MTHFR
    In 330 patients who completed 3 months methotrexate treatment for psoriasis, no significant genotypic associations were found between clinical outcome (e.g. efficacy, toxicity) and 50 SNPs in pathway genes for methotrexate metabolism (ATIC, FPGS, GGH, MTHFR), including 47 common ( >5% minor allele frequency) haplotype-tagging SNPs (r(2) > 0.8) plus 3 additional SNPs.
    Variant Name:
    MTHFR:667C>T
    Related Drugs:
    folic acid, methotrexate
    Related Diseases:
    Psoriasis
    Evidence:
    PMID:19016697
  5. rs2372536 at chr2:215898265 in ATIC
    In 330 patients who completed 3 months methotrexate treatment for psoriasis, no significant genotypic associations were found between clinical outcome (e.g. efficacy, toxicity) and 50 SNPs in pathway genes for methotrexate metabolism (ATIC, FPGS, GGH, MTHFR), including 47 common ( >5% minor allele frequency) haplotype-tagging SNPs (r(2) > 0.8) plus 3 additional SNPs.
    Variant Name:
    ATIC:347C>G
    Related Drugs:
    folic acid, methotrexate
    Related Diseases:
    Psoriasis
    Evidence:
    PMID:19016697
  6. rs70991108 at chr5:79985919 in DHFR, MSH3
    Risk or phenotype-associated allele: del/del Phenotype: Women with the del/del genotype had increased serum and red blood cell folate concentrations. Study size: 197 Study population/ethnicity: Females from the Young Hearts Study; 20-26 years old; Northern Ireland Significance metric(s): p = 0.02 (serum folate); p = 0.16 (red blood cell folate) Type of association: PD
    Variant Name:
    DHFR c.86 + 60_78; DHFR:19bp deletion in intron 1;
    Related Drugs:
    folic acid
    Evidence:
    PMID:18247058
Variant names are different names that have been used in the literature and other resources to refer to the same variant.

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Has annotations
ABCB1
  • CO
  •   
  •   
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCC1
  • CO
  •   
  •   
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCC2
  • CO
  •   
  •   
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCC3
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCC4
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCG2
  • CO
  •   
  •   
  • FA
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
BHMT
  • CO
  • PD
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
BHMT2
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
CBS
  • CO
  • PD
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available No literature annotations Not annotated
CLCN6
  •   
  •   
  •   
  •   
  •   
Variants
Phenotype data available Genotype Data Available Literature annotations available Has annotations
COMT
  •   
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
DHFR
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
FOLR1
  • CO
  • PD
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
FOLR2
  • CO
  • PD
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
FOLR3
  • CO
  •   
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
MSH3
  •   
  •   
  •   
  •   
  •   
Variants
Phenotype data available No genotype data Literature annotations available Not annotated
MTHFD1
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
MTHFD2
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
MTHFR
  • CO
  • PD
  •   
  • FA
  • GN
Publications, Variants
Phenotype data available No genotype data Literature annotations available Not annotated
MTHFS
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
MTR
  • CO
  • PD
  • PK
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
MTRR
  • CO
  • PD
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
NNMT
  • CO
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
NOS3
  • CO
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
SHMT1
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
SLC19A1
  • CO
  • PD
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
SLC46A1
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
TCN1
  •   
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
TYMS
  • CO
  • PD
  •   
  •   
  • GN
Publications

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
FOLR2 Uncurated Annotation (source: Drug Bank)
FOLR3 Uncurated Annotation (source: Drug Bank)
GGH Uncurated Annotation (source: Drug Bank)
SLC25A32 Uncurated Annotation (source: Drug Bank)
SLC46A1 Uncurated Annotation (source: Drug Bank)

PharmGKB Curated Pathways

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

Drug Description
amobarbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
butalbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
hexobarbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
mephenytoin Uncurated Annotation Folic acid decreases the levels of hydantoin (source: Drug Bank)
methylphenobarbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
pentobarbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
phenobarbital Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)
phenytoin Uncurated Annotation Folic acid decreases the levels of hydantoin (source: Drug Bank)
primidone Uncurated Annotation Folic acid decreases the effect of anticonvulsant (source: Drug Bank)

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Adenoma
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Anemia, Megaloblastic
  • CO
  • PD
  • PK
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Chromosome Breakage
  •   
  • PD
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Cleft Lip
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Colorectal Neoplasms
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Heart Defects, Congenital
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Hyperhomocysteinemia
  • CO
  • PD
  • PK
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Hypertension
  • CO
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Leukemia
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Lung Neoplasms
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Malabsorption Syndromes
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Metabolic Diseases
  •   
  •   
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Nervous System Malformations
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Neural Tube Defects
  • CO
  • PD
  • PK
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Spina Bifida Cystica
  • CO
  • PD
  •   
  •   
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00158
ChEBI ID:
27470
KEGG Compound ID:
C00504
KEGG Drug ID:
D00070
PubChem Compound ID:
6037
PubChem Substance ID:
3787

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.